Biochemical and biophysical research communications

Vitamin B6 reduces PD-L1 levels and may boost cancer immunotherapy

Updated

Abstract

Pyridoxal (PL) significantly suppresses PD-L1 expression.

  • The interaction between PD-L1 and PD-1 is known to inhibit T cell activation.
  • Higher levels of PD-L1 in tumor tissues may allow cancer cells to evade the immune system.
  • PL accelerates the degradation of PD-L1 through a process that depends on the proteasome.
  • STUB1 acts as an E3 ligase in the degradation of PD-L1 facilitated by PL.
  • PL enhances the killing activity of T cells by blocking the PD-1/PD-L1 signaling pathway.
  • PL is identified as a potential inhibitor of PD-L1, suggesting a new avenue for combination immunotherapy.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest We declare that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free